Response to high‐dose ifosfamide in patients with advanced/recurrent Ewing sarcoma
The DOI matches its Crossref record.
Abstract
Aim: To determine activity and toxicity of high‐dose ifosfamide (HDIFO) in recurrent or advanced Ewing sarcoma family tumors (EFT). Methods: Thirty‐seven EFT patients [median age 17 years (6–45 years)] previously treated with chemotherapy regimens including standard dose ifosfamide were enrolled. HDIFO was administered for metastatic recurrent disease in 33 patients and for progression during neoadjuvant chemotherapy in 4 patients. All patients who received two courses of 15 g/m 2 ifosfamide were evaluable for radiographic response assessed according to RECIST criteria. Results: Transient Grade 4 neutropenia and thrombocytopenia in 97% and 54% HDIFO courses respectively and severe CNS toxicity in one patient were observed. Thirty‐five patients were evaluable: 12 (34%) had complete (2) or partial (10) response, 11 (32%) had stable disease, and 12 (34%) had progression. Conclusions: In patients with relapsed or advanced EFT previously treated with standard dose ifosfamide HDIFO is active and it should be considered a treatment option. Pediatr Blood Cancer 2009;52:581–584. © 2009 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ewing Sarcoma: Current Management and Future Approaches Through Collaboration
Gaspar, N., Hawkins, D. S., Dirksen, U., Lewis, I. J., Ferrari, S., Le Deley, M.-C., Kovar, H., Grimer, R., Whelan, J., Claude, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5256 · Cited by 722
Self-citationBone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hogendoorn, P. C. W., Athanasou, N., Bielack, S., De Alava, E., Dei Tos, A. P., Ferrari, S., Gelderblom, H., Grimer, R., Sundby Hall, K., Hassan, B., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq223 · Cited by 718
Self-citationCasali, P. G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brennan, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy310 · Cited by 617
Self-citationStrauss, S. J., Frezza, A. M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., Bonvalot, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1995 · Cited by 513
Self-citationEwing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives
Zöllner, S. K., Amatruda, J. F., Bauer, S., Collaud, S., de Álava, E., DuBois, S. G., Hardes, J., Hartmann, W., Kovar, H., Metzler, M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081685 · Cited by 271
Metadata
- Authors
- Ferrari, S., del Prever, A. B., Palmerini, E., Staals, E., Berta, M., Balladelli, A., Picci, P., Fagioli, F., Bacci, G., & Vanel, D.
- Venue
- Pediatric Blood & Cancer
- Publisher
- Wiley
- Published
- 2009-01-13
- Volume
- 52
- Issue
- 5
- Pages
- 581-584
- ISSN
- 1545-5009 (ISSN-L)
- 1545-5017
- OpenAlex
- W2090650007
- Cited by
- 68
- References
- 0
- FWCI
- 2.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Response to high‐dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. https://app.cochat.ai/papers/10.1002/pbc.21917
- The paper
- Ferrari, S., del Prever, A. B., Palmerini, E., Staals, E., Berta, M., Balladelli, A., Picci, P., Fagioli, F., Bacci, G., & Vanel, D. (2009). Response to high‐dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.21917
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.